In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 11, 1999, Pages 2806-2807

  Roblin, Patricia M ^a   Reznik, Tamara ^a   Kutlin, Andrei ^a   Hammerschlag, Margaret R ^a,b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DOXYCYCLINE; ERYTHROMYCIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHLAMYDIA; CHLAMYDOPHILA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0032735444     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.11.2806     Document Type: Article

References (13)

1. Block, S., J. Hedrick, M. R. Hammerschlag, G. H. Cassell, and J. C. Craft. 1995. Mycoplasma pneumoniae and Chlamydia pneumoniae in community acquired pneumonia in children: comparative safety and efficacy of clarithromycin and erythromycin suspensions. Pediatr. Infect. Dis. J. 14:471-477.
2. Cormican, M. G., and R. N. Jones. 1997. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob. Agents Chemother. 41:204-211.
3. Critchley, I. A., J. Broskey, and K. Coleman. 1998. SB-265805 (LB20304a): in vitro activity, intracellular accumulation and killing of Legionella pneumophila in human macrophage, abstr. F-100, p. 257. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Grayston, J. T., L. A. Campbell, C.-C. Kuo, C. H. Mordhorst, P. Saikku, D. H. Thorn, and S. P. Wang. 1990. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J. Infect. Dis. 161:618-625.
5. Hammerschlag, M. R., K. K. Qumei, and P. M. Roblin. 1992. In vitro activity of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:1573-1574.
6. Hammerschlag, M. R. Community-acquired pneumonia due to atypical organisms in adults: diagnosis and treatment. Infect. Dis. Clin. Pract., in press.
7. Hannan, P., and G. Woodnutt. 1998. SB-265805 (LB20304a): susceptibility of human mycoplasmas in vitro, abstr. F-101, p. 257. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Moore, T., N. Niconovich, and K. Coleman. 1998. SB-265805 (LB20304a): in vitro antibacterial activity against the common respiratory tract pathogens Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, abstr. F-98, p. 257. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Oh, J.-I., K.-S. Paek, M.-J. Ahn, M.-Y. Kim, C. H. Hong, I.-C. Kim, and J.-H. Kwak. 1996. In vitro and in vivo evaluation of LB20304, a new fluoronaphthyridone. Antimicrob. Agents Chemother. 40:1564-1568.
10. Ridgway, G. L., N. Salman, S. Clark, I. Mathias, and D. Felmingham. 1998. SB-265805 (LB20304a): comparative in vitro activity against Legionella pneumophila and Chlamydia spp., abstr. F-97, p. 256. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Roblin, P. M., W. Dumornay, and M. R. Hammerschlag. 1992. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J. Clin. Microbiol. 30:1968-1971.
12. Roblin, P. M., A. Kutlin, and M. R. Hammerschlag. 1997. In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 41:2033-2034.
13. Roblin, P. M., and M. R. Hammerschlag. 1998. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 42:951-952.